Is AVXL or AVTX more profitable?

Anavex Life Sciences' return on equity of -38.76% beat Avalo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Anavex Life Sciences N/A -38.76% -35.01% Avalo Therapeutics N/A -97.54% -72.42%

Which has stronger earnings & valuation, AVXL or DSGN?

Design Therapeutics is trading at a lower price-to-earnings ratio than Anavex Life Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anavex Life Sciences N/A N/A -$46.38M -$0.46 N/A Design Therapeutics N/A N/A -$69.79M -$1.20 N/A

Is AVXL or DSGN more profitable?

Design Therapeutics' return on equity of -33.07% beat Anavex Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Anavex Life Sciences N/A -38.76% -35.01% Design Therapeutics N/A -33.07% -31.29%

Which has preferable valuation and earnings, REPL or AVXL?

Anavex Life Sciences is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Replimune Group N/A N/A -$313.94M -$3.38 N/A Anavex Life Sciences N/A N/A -$46.38M -$0.46 N/A

Is REPL or AVXL more profitable?

Anavex Life Sciences' return on equity of -38.76% beat Replimune Group's return on equity. Company Net Margins Return on Equity Return on Assets Replimune Group N/A -128.57% -82.35% Anavex Life Sciences N/A -38.76% -35.01%

Anavex Life Sciences (AVXL) Competitors

$2.40 +0.05 (+1.91%)

As of 11:13 AM Eastern

Compare

AVXL vs. AVTX, KURA, DSGN, PHAR, and REPL

Should you buy Anavex Life Sciences stock or one of its competitors? MarketBeat compares Anavex Life Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Anavex Life Sciences include Avalo Therapeutics (AVTX), Kura Oncology (KURA), Design Therapeutics (DSGN), Pharming Group (PHAR), and Replimune Group (REPL). These companies are all part of the "pharmaceutical products" industry.

How does Anavex Life Sciences compare to Avalo Therapeutics?

Anavex Life Sciences (NASDAQ:AVXL) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, dividends and analyst recommendations.

Anavex Life Sciences has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market. Comparatively, Avalo Therapeutics has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market.

Anavex Life Sciences has higher earnings, but lower revenue than Avalo Therapeutics. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.46	N/A
Avalo Therapeutics	$60K	16,439.52	-$78.26M	-$5.46	N/A

31.6% of Anavex Life Sciences shares are owned by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are owned by institutional investors. 11.0% of Anavex Life Sciences shares are owned by company insiders. Comparatively, 4.5% of Avalo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Avalo Therapeutics had 2 more articles in the media than Anavex Life Sciences. MarketBeat recorded 3 mentions for Avalo Therapeutics and 1 mentions for Anavex Life Sciences. Anavex Life Sciences' average media sentiment score of 1.87 beat Avalo Therapeutics' score of 0.70 indicating that Anavex Life Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
Anavex Life Sciences	Very Positive
Avalo Therapeutics	Positive

Anavex Life Sciences' return on equity of -38.76% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anavex Life Sciences	N/A	-38.76%	-35.01%
Avalo Therapeutics	N/A	-97.54%	-72.42%

Anavex Life Sciences presently has a consensus price target of $21.33, indicating a potential upside of 794.48%. Avalo Therapeutics has a consensus price target of $45.80, indicating a potential upside of 144.10%. Given Anavex Life Sciences' higher possible upside, equities research analysts plainly believe Anavex Life Sciences is more favorable than Avalo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86

Summary

Anavex Life Sciences beats Avalo Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Anavex Life Sciences compare to Kura Oncology?

Kura Oncology (NASDAQ:KURA) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Kura Oncology currently has a consensus target price of $25.46, suggesting a potential upside of 125.92%. Anavex Life Sciences has a consensus target price of $21.33, suggesting a potential upside of 794.48%. Given Anavex Life Sciences' higher probable upside, analysts clearly believe Anavex Life Sciences is more favorable than Kura Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Anavex Life Sciences has lower revenue, but higher earnings than Kura Oncology. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kura Oncology	$67.48M	14.83	-$278.67M	-$3.35	N/A
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.46	N/A

In the previous week, Kura Oncology had 8 more articles in the media than Anavex Life Sciences. MarketBeat recorded 9 mentions for Kura Oncology and 1 mentions for Anavex Life Sciences. Anavex Life Sciences' average media sentiment score of 1.87 beat Kura Oncology's score of 1.25 indicating that Anavex Life Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Kura Oncology	Positive
Anavex Life Sciences	Very Positive

31.6% of Anavex Life Sciences shares are owned by institutional investors. 7.6% of Kura Oncology shares are owned by insiders. Comparatively, 11.0% of Anavex Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Kura Oncology has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market. Comparatively, Anavex Life Sciences has a beta of 1.14, meaning that its stock price is 14% more volatile than the broader market.

Anavex Life Sciences has a net margin of 0.00% compared to Kura Oncology's net margin of -411.19%. Anavex Life Sciences' return on equity of -38.76% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kura Oncology	-411.19%	-141.95%	-43.28%
Anavex Life Sciences	N/A	-38.76%	-35.01%

Summary

Anavex Life Sciences beats Kura Oncology on 10 of the 15 factors compared between the two stocks.

How does Anavex Life Sciences compare to Design Therapeutics?

Anavex Life Sciences (NASDAQ:AVXL) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

Design Therapeutics is trading at a lower price-to-earnings ratio than Anavex Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.46	N/A
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A

In the previous week, Design Therapeutics had 1 more articles in the media than Anavex Life Sciences. MarketBeat recorded 2 mentions for Design Therapeutics and 1 mentions for Anavex Life Sciences. Design Therapeutics' average media sentiment score of 1.89 beat Anavex Life Sciences' score of 1.87 indicating that Design Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Anavex Life Sciences	Very Positive
Design Therapeutics	Very Positive

Anavex Life Sciences has a beta of 1.14, suggesting that its share price is 14% more volatile than the broader market. Comparatively, Design Therapeutics has a beta of 1.58, suggesting that its share price is 58% more volatile than the broader market.

Design Therapeutics' return on equity of -33.07% beat Anavex Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anavex Life Sciences	N/A	-38.76%	-35.01%
Design Therapeutics	N/A	-33.07%	-31.29%

31.6% of Anavex Life Sciences shares are owned by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are owned by institutional investors. 11.0% of Anavex Life Sciences shares are owned by insiders. Comparatively, 17.1% of Design Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Anavex Life Sciences presently has a consensus price target of $21.33, suggesting a potential upside of 794.48%. Design Therapeutics has a consensus price target of $16.50, suggesting a potential upside of 21.02%. Given Anavex Life Sciences' higher possible upside, equities research analysts clearly believe Anavex Life Sciences is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Design Therapeutics beats Anavex Life Sciences on 10 of the 14 factors compared between the two stocks.

How does Anavex Life Sciences compare to Pharming Group?

Anavex Life Sciences (NASDAQ:AVXL) and Pharming Group (NASDAQ:PHAR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings.

Pharming Group has a net margin of 3.30% compared to Anavex Life Sciences' net margin of 0.00%. Pharming Group's return on equity of 4.64% beat Anavex Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anavex Life Sciences	N/A	-38.76%	-35.01%
Pharming Group	3.30%	4.64%	2.55%

31.6% of Anavex Life Sciences shares are owned by institutional investors. Comparatively, 0.0% of Pharming Group shares are owned by institutional investors. 11.0% of Anavex Life Sciences shares are owned by insiders. Comparatively, 2.1% of Pharming Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Anavex Life Sciences has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market. Comparatively, Pharming Group has a beta of -0.04, indicating that its stock price is 104% less volatile than the broader market.

Pharming Group has higher revenue and earnings than Anavex Life Sciences. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.46	N/A
Pharming Group	$376.13M	2.51	$2.85M	$0.16	83.66

In the previous week, Pharming Group had 1 more articles in the media than Anavex Life Sciences. MarketBeat recorded 2 mentions for Pharming Group and 1 mentions for Anavex Life Sciences. Anavex Life Sciences' average media sentiment score of 1.87 beat Pharming Group's score of 1.77 indicating that Anavex Life Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
Anavex Life Sciences	Very Positive
Pharming Group	Very Positive

Anavex Life Sciences currently has a consensus target price of $21.33, indicating a potential upside of 794.48%. Pharming Group has a consensus target price of $38.33, indicating a potential upside of 186.39%. Given Anavex Life Sciences' higher possible upside, analysts plainly believe Anavex Life Sciences is more favorable than Pharming Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Pharming Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Pharming Group beats Anavex Life Sciences on 8 of the 13 factors compared between the two stocks.

How does Anavex Life Sciences compare to Replimune Group?

Replimune Group (NASDAQ:REPL) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

Anavex Life Sciences' return on equity of -38.76% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Replimune Group	N/A	-128.57%	-82.35%
Anavex Life Sciences	N/A	-38.76%	-35.01%

Replimune Group has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market. Comparatively, Anavex Life Sciences has a beta of 1.14, suggesting that its stock price is 14% more volatile than the broader market.

92.5% of Replimune Group shares are owned by institutional investors. Comparatively, 31.6% of Anavex Life Sciences shares are owned by institutional investors. 5.2% of Replimune Group shares are owned by company insiders. Comparatively, 11.0% of Anavex Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Replimune Group presently has a consensus price target of $8.13, indicating a potential downside of 18.49%. Anavex Life Sciences has a consensus price target of $21.33, indicating a potential upside of 794.48%. Given Anavex Life Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Anavex Life Sciences is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Replimune Group	2 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Anavex Life Sciences is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Replimune Group	N/A	N/A	-$313.94M	-$3.38	N/A
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.46	N/A

In the previous week, Replimune Group had 4 more articles in the media than Anavex Life Sciences. MarketBeat recorded 5 mentions for Replimune Group and 1 mentions for Anavex Life Sciences. Anavex Life Sciences' average media sentiment score of 1.87 beat Replimune Group's score of 0.88 indicating that Anavex Life Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Replimune Group	Positive
Anavex Life Sciences	Very Positive

Summary

Anavex Life Sciences beats Replimune Group on 10 of the 13 factors compared between the two stocks.

Get Anavex Life Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVXL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVXL vs. The Competition

Export

Metric	Anavex Life Sciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$221.02M	$3.64B	$6.76B	$12.50B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-5.18	20.96	26.93	24.41
Price / Sales	N/A	313.81	586.18	117.36
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	2.17	8.50	10.94	6.33
Net Income	-$46.38M	$23.83M	$3.58B	$330.66M
7 Day Performance	-11.99%	-3.12%	-2.10%	-0.66%
1 Month Performance	-4.60%	6.61%	3.21%	-0.14%
1 Year Performance	-79.22%	48.58%	26.34%	20.16%

Anavex Life Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVXL Anavex Life Sciences	2.8451 of 5 stars	$2.40 +1.9%	$21.33 +790.7%	-78.8%	$221.95M	N/A	N/A	40	Positive News Upcoming Earnings
AVTX Avalo Therapeutics	3.0318 of 5 stars	$19.96 +5.9%	$45.80 +129.5%	+295.6%	$990.34M	$60K	N/A	40
KURA Kura Oncology	2.8766 of 5 stars	$11.04 -0.5%	$25.46 +130.6%	+73.7%	$985.40M	$67.48M	N/A	130	News Coverage Positive News
DSGN Design Therapeutics	2.1714 of 5 stars	$14.85 -5.1%	$16.50 +11.1%	+253.3%	$976.83M	N/A	N/A	40	News Coverage
PHAR Pharming Group	3.4521 of 5 stars	$14.31 +3.9%	$38.33 +167.9%	+37.0%	$972.51M	$376.13M	89.44	280	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AVXL) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Anavex Life Sciences (AVXL) Competitors

AVXL vs. AVTX, KURA, DSGN, PHAR, and REPL

How does Anavex Life Sciences compare to Avalo Therapeutics?

Summary

How does Anavex Life Sciences compare to Kura Oncology?

Summary

How does Anavex Life Sciences compare to Design Therapeutics?

Summary

How does Anavex Life Sciences compare to Pharming Group?

Summary

How does Anavex Life Sciences compare to Replimune Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVXL vs. The Competition

Anavex Life Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Anavex Life Sciences (AVXL) Competitors

AVXL vs. AVTX, KURA, DSGN, PHAR, and REPL

How does Anavex Life Sciences compare to Avalo Therapeutics?

Which has more risk and volatility, AVXL or AVTX?

Which has stronger valuation & earnings, AVXL or AVTX?

Do insiders and institutionals have more ownership in AVXL or AVTX?

Does the media refer more to AVXL or AVTX?

Is AVXL or AVTX more profitable?

Do analysts recommend AVXL or AVTX?

Summary

How does Anavex Life Sciences compare to Kura Oncology?

Do analysts recommend KURA or AVXL?

Which has better earnings and valuation, KURA or AVXL?

Does the media refer more to KURA or AVXL?

Do insiders & institutionals have more ownership in KURA or AVXL?

Which has more volatility and risk, KURA or AVXL?

Is KURA or AVXL more profitable?

Summary

How does Anavex Life Sciences compare to Design Therapeutics?

Which has stronger earnings & valuation, AVXL or DSGN?

Does the media favor AVXL or DSGN?

Which has more risk & volatility, AVXL or DSGN?

Is AVXL or DSGN more profitable?

Do institutionals and insiders have more ownership in AVXL or DSGN?

Do analysts prefer AVXL or DSGN?

Summary

How does Anavex Life Sciences compare to Pharming Group?

Is AVXL or PHAR more profitable?

Do institutionals & insiders believe in AVXL or PHAR?

Which has more risk & volatility, AVXL or PHAR?

Which has higher earnings and valuation, AVXL or PHAR?

Does the media refer more to AVXL or PHAR?

Do analysts rate AVXL or PHAR?

Summary

How does Anavex Life Sciences compare to Replimune Group?

Is REPL or AVXL more profitable?

Which has more risk and volatility, REPL or AVXL?

Do institutionals and insiders believe in REPL or AVXL?

Do analysts rate REPL or AVXL?

Which has preferable valuation and earnings, REPL or AVXL?

Does the media refer more to REPL or AVXL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVXL vs. The Competition

Anavex Life Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools